Endo Laboratories

Endo is a specialty pharmaceutical company that develops, manufactures, and distributes branded and generic pharmaceutical products. The company is particularly known for its leadership in urology, orthopedics, and medical aesthetics, with its flagship product Xiaflex treating conditions like Dupuytren's contracture and Peyronie's disease. Endo also maintains a significant presence in the sterile injectables and generics markets through its subsidiaries like Par Pharmaceutical and its Endo Laboratories division. After undergoing a comprehensive financial restructuring due to opioid-related litigation, the company emerged in April 2024 as Endo, Inc. It is now a private entity focused on sustainable growth and expanding its portfolio of specialty medicines. The company operates major facilities in the United States, Ireland, and India.